Barclays’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Barclays’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-784,500	Closed	-$135M	–	7495
2015 Q1	$135M	Buy	784,500 +711,800	+979%	+$104M	0.16%	109
2014 Q4	$8.29M	Sell	72,700 -2,600	-3%	-$315K	0.01%	1320
2014 Q3	$11.7M	Buy	75,300 +33,700	+81%	+$4.89M	0.01%	1057
2014 Q2	$5.12M	Sell	41,600 -6,300	-13%	-$696K	0.01%	1727
2014 Q1	$4.93M	Sell	47,900 -52,000	-52%	-$5.32M	0.01%	1704
2013 Q4	$8.89M	Buy	99,900 +95,500	+2,170%	+$7.62M	0.01%	1342
2013 Q3	$290K	Buy	4,400 +1,000	+29%	+$68.9K	﹤0.01%	4688
2013 Q2	$225K	Buy	+3,400	New	+$194K	﹤0.01%	5055

Other funds holding SLXP

MMG

Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

Barclays's SLXP Position: Q2 2015 in Review

Barclays sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 303,956 shares — an estimated $52.3M sold.

Barclays first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $52.3M in Q1 2015. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

Barclays reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
Barclays sold 303,956 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $52.3M.
Barclays first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
Barclays's SALIX PHARMACEUTICALS LTD DEL position peaked at $52.3M in Q1 2015.
1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Barclays's 13F filing for Q2 2015, filed 14 Aug 2015.